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Polymorphonuclear leukocytes (PMNL)' are known to play an important role in
acute inflammatory processes (1) as well as in some chronic disease conditions such
as rheumatoid arthritis (2) and psoriasis (3) . Anumber ofneutrophil chemotactic
factors appear to be involved in the tissue accumulation ofPMNL, including C5a
(4), bacterial F-Met peptides (5), the platelet-activating factorPAF (6), and leukotriene
B4 (LTB4) (7) . In addition to these well-characterized chemotaxins there is now
ample evidence thatupon stimulation host cells themselves areable to respond with
the release of protein-likePMNL chemotactic factors . Although several studies re-
vealed theexistence of such biological activity (8-12), until recently the factors respon-
sible forPMNL chemotactic activity were not biochemically purified and charac-
terized .
In previous studieswe as well as others have purified anovel neutrophil-activating
cytokine obtained from LPS- or mitogen-stimulated humanmononuclear cells, which
was termed MONAP (13), MDNCF (14), NAF (15), LYNAP (16), or chemotactic
monokine (17), all being identical by N112-terminal amino acid sequencing (14, 15,
17, 18). More recently, this cytokine was tentatively termed neutrophil-activating
peptide or interleukin 8 (NAP/IL-8) (19, 20). NAP/IL-8 is aß.â59-kD polypeptide
containing 72 amino acid residues ofwhich the complete amino acid sequence was
recently determined (18) . The amino acid sequence ofNAPAL-8, which also has
been clonednow (21), is identical to thededuced aminoacid sequence ofafragment
of the 3-10C cDNA sequence (22) . So far NAP/IL-8 appears to be a polypeptide
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with 30-40% structural homology to platelet-derived polypeptides, such as platelet
factor 4, a-thromboglobulin, connective tissue activating peptide III, as well as other
host defense cytokines such as IFN-y-inducible protein IP-10, 9E3 from Rous sar-
coma-induced chicken fibroblasts, and a mitogen called melanoma growth stimulating
activity (MGSA) (16, 18, 21, 23). Purified NAP/IL-8 shows potent chemotatic ac-
tivity for human neutrophils in vitro (13, 14, 16, 17), activates the release ofsuperoxide
anions (13, 24), and elicits release ofthe primary granule constituents from neutro-
phils (myeloperoxidase, /3-glucuronidase, and elastase) (13, 15, 24).
The neutrophil-activating mediators C5a, FMLP, and PAF, all ofwhich are known
to bind to ligand-specific membrane receptors on neutrophils, have been shown to
activate the arachidonate-5-lipoxygenase with the release of LTB4 by human neu-
trophils in the presence of exogenous arachidonic acid (AA) (25-27).
The biological similarity of NAP/IL-8 to other clearly characterized neutrophil
chemoattractants raises the question whether this novel cytokine is also able to stimulate
the neutrophil arachidonate-5-lipoxygenase with the release ofneutrophilchemotactic
leukotrienes in the presence or the absence of extracellular AA.
In this article we report that NAP/IL-8 at concentrations relevant in vivo is able
to stimulate the release of LTB4 in the presence of exogenous AA.
Materials and Methods
Neutrophil Isolation.
￿
Human PMNL were isolated using a modification of the method of
Henson (28), similar to a method previously described (29). Briefly, venous bloodwas drawn
into 1/6 vol of acidic citrate/dextran (0.085 mol/liter sodium citrate, 0.065 mol/liter citric
acid in double-distilled, pyrogen-free water containing 2% (wt/vol) Dextran T 70 (Pharmacia
Fine Chemicals, Uppsala, Sweden), centrifuged, and the supernatant containing plasma,
platelets, and mononuclear cells was removed. The sediment containing E and PMNL was
mixed with gelatine solution (2.5% (wt/vol) in 0.9% NaCl) and E were allowed to sediment
for 30 min at 37°C. PMNL-rich supernatants were collected and contaminating red cells
were lysed by 0.85% (wt/vol) NH4Cl for 7 min at room temperature followed by two washes
with PBS. Contaminating platelets were separated by threefold low speed centrifugation of
the final neutrophil preparation through 2 % (wt/vol) BSA in PBS (30). Finally, PMNLwere
suspended in CaC12/MgC12-free PBS and stored at 4°C until further use. Viability of the
final PMNL preparation usually was better than 97% by usingthe trypan blue dye exclusion
test. Eosinophil contamination did not exceed 517o ofthe final granulocyte preparation. PMNL
preparations with higher eosinophil contamination were not used in these experiments.
NAP/IL-8 Assay.
￿
NAP/IL-8 was detected in HPLC column fractions by two different
methods as recently described in detail (13). When high amounts of NAP-IL-8 were expected
an PMNL enzyme release assay was used. Briefly, PMNL (107 cells/ml PBS) were prein-
cubated with cytochalasin B (5 kg/ml, Sigma Chemical Co., Munich, FRG) and thereafter
stimulated with column fractions at appropriate dilutions in complete PBS (cPBS, PBS con-
taining 0.1% [wt/vol] BSA, 0.9 mM CaC12, and 0.49 MM MgCl2) for 30 min. In some cases
fractions were lyophilized before the degranulation assay. After centrifugation, cell-free su-
pernatants were tested for myeloperoxidase release as described (13). When low amounts of
NAP/IL-8 were expected, as well as for determination ofchemotactic lipids, an indirect PMNL
chemotaxis assay was used as described (13).
Production of NAP/IL-8.
￿
A mixture of human mononuclear cells obtained after Ficoll
medium separation of venous blood anticoagulated with 1 mM EDTA as described (13) was
incubated with LPS (Salmonella Minnesota RE 595, Calbiochem-Behring Corp., Marburg,
FRG; 1 pg/ml) together with PHA (10 Wg/ml) in RPMI containing 20 mM Hepes (cell den-
sity: 5 x 106 cells/ml) using plastic tissue culture flasks (Falcon Labware, Oxnard, CA) inSCHRODER
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a humidified atmosphere containing 5% CO2 at 37oC. After 40-48 h of incubation, condi-
tioned media were collected and frozen below -70'C until further use.
NAP/IL-8 Purification.
￿
NAP/IL-8 was purified to homogeneity as recently described (13).
Briefly, supernatants ofLPS/PHA-stimulated mononuclear cells were acidified, and aftercen-
trifugation the supernatants were chromatographed on a G-75-Sephadex gelcolumn (Phar-
macia Fine Chemicals). NAP/IL-8 eluting in the 5-20-kD area was further purified by se-
quentially performed wide pore RP-8-HPLC (Zorbax PEP-RP-1; Dupont, Bad Nauheim,
FRG), TSK-2000 3 SWHPLC (LKB, Bromma, Sweden; 0.8 x 60 cm), and finally, narrow
pore RP-18-HPLC (Nudeosil, 5 pm-octadecyl silica-column; Macherey-Nagel, Duren, FRG),
as described (13). Purity of NAP/IL-8 was ascertained by SDS-PAGE under nonreducing
conditions in the presence of 6 M urea using a recently optimized method for detection of
polypeptides (31). NAPAL-8 preparations were free of endotoxin as revealed by the Limulus
lysate assay (Sigma Chemical Co.).
In experiments where PMNL-5-lipoxygenase stimulating activity should be determined
in crudesupernatants of stimulated mononuclear cells, these first were chromatographed on
a G-75-gel column, as described before, followed by a preparative wide pore RP-8-HPLC
separation. Biologically active G-75-gel column fractions (5-20-kD pool) were applied directly
to a preparative wide pore RP-8-HPLC column (300-7C8 Nucleosil, 250 x 12.6 mm;
Macherey-Nagel) and eluted from the column usinga gradient of increasing concentrations
ofacetonitrile in 0.1% TFA. During the HPLC separation of peptides absorbancewas moni-
tored at 215 nm. Integration values obtained by the peak integrator (Spectra Physics SP 4270)
were used to determine the amounts of peptides and proteins eluting in a given peak. To
convert integration units to protein concentrations, known amounts of ubiquitine (Sigma
Chemical Co.) were used for calibration. Nearly 106 integration units corresponded to 1 Wg
ubiquitine.
RP-8-HPLC-purified, PMNL-5-LO-stimulating peptides were further purified by wide
pore CN-propyl-RP-HPLC (5 urn, 250 x 4.6 mm; J. T. Baker Chemical Co., Gross Gerau,
FRG). Peptides eluted with a gradient ofincreasing concentrations ofn-propanol containing
0.1% TFA. If necessary, fractions containing PMNL-5-LO-stimulating activity offCN-propyl-
RP-HPLC were finally purified with a narrow pore RP-18-HPLC column using a gradient
of increasing concentrations of acetonitrile as described (13).
Activation ofPMNL-5-Lipoxygenase.
￿
Purified neutrophils (10' cells) suspended in 1 ml PBS
(without CaC12 and MgC12) were preincubated with exogenously added arachidonic acid at
the desired concentration (prepared by solubilization of an aliquot of an arachidonic acid
stock [1 mg/ml ethanol] in 20 pl 0.1 mol/1 NaHCO3 solution after blowing up the ethanol
with argon and dilution with 0.5 ml PBS) for 5 min at 37°C. Thereafter, 40 Al of a stock
of CaC12 (90 mmol/liter) and MgCl2(49 mmol/liter) followed by a prewarmed (37°C) solu-
tion ofNAP/IL-8 in PBS was added. NAP/IL-8 stored as a stock solution (100 pg/ml) in acetoni-
trile containing 0.1 % TFA below - 70°C, was freshly prepared by lyophilization and solubili-
zation of the residue in PBS just before experiments were started. Cells were incubated for
the desired time at 37 oC and the vials thereafter were cooled to 0°C in an ice-water bath.
After centrifugation at VC, supernatants were collected and 100 ng PGB2 (Sigma Chem-
ical Co.) in 10 pl methanol, as well as the radical scavenger 4-hydroxy-2,2,6,6-tetramethyl-
piperidinooxy free radical (2 hg) (Sigma), was added. Samples were stored below - 70'C
until HPLC analysis of eicosanoids.
RP-HPLC Quantitation of Nonradioactive Eicosanoids.
￿
RP-HPLC analysis of the superna-
tants was performed with a Cis Nucleosil-ODS 2-HPLC-column (4.6 x 250 mm) (Bischoff,
Leonberg, FRG). Supernatants were extracted by the use of a precolumn cartridge (RP-18-
silica) similar to the method described by Powell (32) by pressing the total volume of the su-
pernatant (N2 ml) containing 10% (vol/vol) methanol through the precolumn, which previ-
ously was equilibrated with 0.1°Jo (wt/vol) ammoniumphosphate, pH 4.5 (solvent A), followed
by washing the precolumn with 1 ml solvent A and then 2 ml solvent A, containing 40%
(vol/vol) HPLC grade methanol (solvent B).
The HPLC-column was equilibrated with 50° Jo A and 50% B and the lipids focused onto850
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the precolumn eluted by a gradient of increasing amounts of methanol with the following
protocol: time 0 min: 50% A, 50% B; time 6 min: 60% A, 40% B; time 12 min: 60% A,
40% B; time 28 min: 70% A, 30% B; time 50 min: 70% A, 30 B; time 52 min: 100% A;
time 65 min: 100% A. A flow rate of 1.0 ml/min at 50°C was maintained and the effluent
was monitored at 270 nm (leukotrienes) or 237 nm (monohydroxy acids).
Peak areas were integrated using a Spectra Physics computing integrator (SP 4270) and
the amounts ofleukotrienes were calculated by calibration ofthe column with known amounts
of authentic samples of 20-COOH-LTB4 (Paesel, Frankfurt, FRG), 20-OH-LTB4 (Paesel),
LTB4 (Paesel), and 5-HETE (a generous gift of Dr. Bartmann, Hoechst-AG, Frankfurt,
FRG). All values were corrected for recovery by the use of the internal standard PGB2.
Experiments with the Use ofPHJAA.
￿
In some cases PMNL-5-LO activation experiments
were performed in the presence of [3H]AA (Amersham, Braunschweig, FRG). [3H]AA
(specific activity, 201.5 Ci/mmol) dissolved in ethanol (250 ACi/ml) was treated with 10 P,1
0.1 mol/liter NaHC03, pH 9, and the ethanol was blown up under a stream of argon. The
residue was dissolved in PBS and the [3H]AA solution was immediately used thereafter at
desired concentrations.
Some experiments were performed identically tothat described under"Activation ofPMNL-5
Lipoxygenase; whereby 2.5 tzCi [3H]AA was added just before CaC12/MgC12 was given to
the cell suspension (10' PMNL) to minimize incorporation of [3H]AA into the cellular mem-
brane. In other experiments, 10' PMNL were incubated with 5 jACi [3H]AA in 2 ml of PBS
containing 0.9 mmol/liter CaC12 and 0.5 mmol/liter MgC12 for 1 h at 37°C. Thereafter cells
were washed three times with PBS and suspended in 1 ml PBS. To 10' prelabeled and
prewarmed (37°C) PMNL in 1 ml PBS, 40 Al CaC12 (90 mmo1/1) containing 50 mmol/liter
MgC12 was added followed by 0.5 ml of the stimulus in PBS or PBS alone with subsequent
incubation for 30 min at 37 °C. After centrifugation supernatants were frozen below -70°C
under argon or applied directly to RP-HPLC. Radioactivity was monitored by on-line
counting, whereby the column eluate was mixed with liquid scintillant (2 ml/min; Rialuma;
J. T. Baker Chemical Co.) and counted in a 1 ml flow cell.
Results
Detection ofa PMNL 5-Lipoxygenase-activating Factor in LPS/PHA-stimulated Mononu-
clear Cell Supernatants. When human PMNL were stimulated with crude superna-
tants of LPS/PHA-stimulated mononuclear cells in the presence of 5 x 10-6 mol/
liter exogenous AA, significant amounts of 20-COOH-LTB4, 20-OH-LTB4, both
trans-isomers of LTB4, as well as LTB4, were detectable in supernatants analyzed
by RP-HPLC (data not shown). When partially purified (G-75-gel filtration) mono-
nuclear cell supernatants were applied to a preparative wide pore RP-8-HPLC column,
LTB4 synthesis-inducing activity eluted in a single fraction (Fig. 1), corresponding
to a UV peak absorbing at 215 nm. This fraction also contained potent PMNL
chemotactic activity (data not shown). IL-1, which is also present in supernatants
of LPS-stimulated mononuclear cells, eluted several minutes later than PMNL che-
motactic activity (Fig. 1). In these fractions as well as in others no significant LTB4
synthesis-inducing activity could be detected, even when 200-p.1 aliquots of frac-
tions were tested.
Evidence that NAPlIL-8 Is a PMNL-5-Lipoxygenase Activator.
￿
Fractions containing
5-LO-stimulating activity were purified to homogeneity by additional CN-propyl-
HPLC off RP-8-HPLC-purified material (Fig. 2). Major activity eluted in a peak
absorbing at 215 nm, which demonstrates an intense line at 10 kD upon SDS-PAGE
with an additional faint band from a 5-kD trace contaminant (Fig. 2). The SDS-
PAGE profile was indistinguishable from that obtained from authentic NAP/IL-8
that has been purified to homogeneity. We also have detected the minor contaminantSCHRODER
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FIGURE 1.
￿
Preparative wide pore RP-8-HPLC-profile ofG-75-gel chromatography purified su-
pernatants ofLPSIPHA-stimulated humanmononuclearcells. Supernatants ofhumanmononuclear
cells (4 x 108 cells containing 30% monocytes) were partially purified on a G-75-gel column
andbiologically active fractions(5-20kD area)were separatedon apreparative wide pore RP-8-
HPLC column usingtheprogramindicatedin Materials and Methods. Elution of thepeptides
was monitored at 215 nm. 20 pl aliquots of each fraction were tested for LTB4 production in
PMNL usingthe protocol described in Materialsand Methods. Thetotalamount of LTB4 pro-
duced by 10 PMNL (sum of LTB4, 20-OH-LTB4, and 20-COOH-LTB4) within 10 min incu-
bation is indicated (shadedbars). Note the appearance of asingle LTB4 synthesis-inducing peak
and the absence of such activity in fractions containing IL-1 (the elution position of authentic
IL-10 is indicated by the arrow).
representing possibly a shorter fragment of NAP/IL-8 in NAP/IL-8 preparations
purifiedbyNAP/IL-8 affinity chromatography followed by RP-18-HPLC (Schrader,
J.-M., and M. Sticherling, unpublished results).
When human PMNL were exposed to 6 x 10-$ mol/liter NAP/IL-8 in the pres-
ence of8 x 10-6 mol/liter AA, several intense UVabsorbing peaks were detected,
as shown in a typical chromatogram (Fig. 3A). In the absence ofNAP/IL-8, nearly
no UV-absorbing peakscouldbe seen inthe leukotriene/HETE area(Fig. 3B)when
PMNL were incubated with 8 x 10-6 mol/liter AA only.
Peaks absorbing at 270 nm were identified to be 20-COOH-LTB4 (10.9 min), 20-
OH-LTB4 (12.7 min), trans-LTB4 (21.1 min), epi-trans-LTB4 (21.8 min), and LTB4
(22.9 min). A peak absorbing at 237 nm was identified to be 5-HETE (35.5 min).
This was proven by further experiments with authentic samples that were applied
to the same column. These eluted from the column exactly at the same retention852
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Final purification step of
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the LTB4 synthesis-inducing cytokine.
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RP-8-HPLC-purified LTB4 synthe-
sis-inducing peptides (Fig. 1) were
a
￿
finally purified by wide pore cyano-
propyl-HPLC with a gradient of n-pro
Q
￿
panol using a protocol indicated in
MaterialsandMethods. Elution ofthe
peptides wasmonitored at 215 nm. A
major LTB4 production-inducing
®
￿
cytokine (detectedasdescribedin Fig.
1 and Materials and Methods; shaded
w
￿
bars)elutes at 16 minfrom the column
corresponding to a single absorbing
G
￿
peptide peak at 215-nm. This fraction
demonstrated, upon SDS-PAGE under
g'
￿
nonreducing conditions, amajorband
near 10 kD andafaintband near 5kD
m (inset).
time and demonstrated a single peak when co-injected with the expected eicosa-
noids either upon RP-HPLC orSP-HPLC (data not shown). Furthermore, all 270-
nm absorbing peaks were collected, separately pooled, and analyzed for their UV
spectrum in a double-beam spectrophotometer. The presence of triple absorption
peaks near 260, 270, and 280 nm for fractions eluting at 10.9, 12.7, 21.1, 21.8, and
22.9 min, revealed that all these fractions contain material with a conjugated triene
structure. The peak eluting at 35.5 min demonstrated a UV maximum at 237 nm,
which is typical for a conjugated cis, traps-diene as 5-HETE is too. In addition, frac-
tionswere lyophilized and analyzed forPMNL chemotactic activity using theBoyden
chamber method at final leukotriene concentrations calculated by UV absorbance
at 270 nm to be between 10 and 0.1 ng/ml. Half-maximal chemotactic responsehas
been found at 0.4 ng/ml for the peak eluting at 22.9 min, which fits well with the
ED50 found in our laboratory for authentic LTB4.
The presence ofchemotactic activity in fractions corresponding to the retention
times ofauthentic LTB4 and 20-OH-LTB4 at concentrations known to be active in
authentic material gives additional evidence that these both major metabolites are
indeed 20-OH-LTB4 and LTB4 and not 5-(S),12(S)-DiHETE, or its metabolites,
whichareknown tolackPMNL chemotacticactivity. Moreover, straight phase HPLC
ofpooled "LTB4"-peaks, obtained after RP-HPLC ofNAP/IL-8-stimulated PMN,
revealed retention time identical to that ofauthentic LTB4, and only traces of5(S),
12(R)-DiHETE (data not shown).a PGBl Y
￿
B
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FIGURE 3.
￿
RP-HPLCanalysis
ofthemonoHETE anddiHETE
derivatives in supernatant fluids
isolated from 107 PMNL. (A)
PMNL were treated with 6 x
10-8 mol/liter NAP/IL-8 for 15
min at 37°C in thepresence of
8 x 10-6 mol/liter exogenous
AA. AAmetabolites were moni-
tored by UV absorption at 270
nm (diHETEs) and 237 nm
(monoHETEs). Compounds
I-VII were identified to be
20-COOH-LTB4 (I), 20-OH-
LTB4 (II), A6-trans-LTB4 (III),
12-epi-A6-trans-LTB4 (IV),
LTB4 (V); and 5-HETE (VI).
Shaded bars indicate PMNL
chemotactic indices of an ali-
quot ofpeak fractions at 1:100
rim [mm]
￿
rlm.[,.]
￿
dilution, except 5-HETE, which
a
￿
wastested at 1:2 dilution as de-
Cr
￿
scribed in Materials and Meth-
ods. The chemotactic index of
Meth-
2W
￿
authenticLTB4 at 1 ng/ml has
been found to be 3.8 (buffer
control, 1.0) for PMNL. (B)
PMNL were treated with 8 x
10-6 mol/literAA for 5 min. at
ao
￿
ao
￿
.0
￿
37°C. Note the same attenua-
rim. t-l
￿
tion as in A. Determination of
PMNL chemotactic activity in
column fractions identical to that collected in A at the same dilution did not reveal any significant
chemotactic activity (data not shown). (C) PMNL were exposed to 6 x 10-s mol/liter NAP/IL-8 in
the presence of 6 x 10-7 mol/liter AA containing [3H]AA (specific activity in this experiment, 3 Ci/
mmol).
Supernatantfluids were separatedby RP-HPLCandanalyzed forradioactivity as describedin Materials
and Methods. Note the presence of radioactive peaks at elution time nearly identical to that of UV
absorbing peaks in A. VII indicates the elution time of [ 3H]AA.
owe 0000"
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In other experiments PMNL were stimulated with NAP/IL-8 in the presence of
6 x 10' mol/liter [3H]AA (specific activity in these experiments: 3 Ci/mol). Now
radioactive peaks were detectable in the position of authentic LTB4, 20-OH-LTB4,
and 5-HETE (Fig. 3 C), confirming the results shown in Fig. 3 A that these peaks
indeed derive from AA metabolites.
Dose Response ofNAP1IL-8-induced LTB4 Production.
￿
When 10' PMN were stimu-
lated with different doses of NAP/IL-8 in the presence of 8.2 x 10-6 mol/liter ex-
ogenous AA for 5 min, a dose-dependent increase of LTB4 production was observ-
able (Fig. 4). Maximal total LTB4 production (sum of 20-COOH-LTB4,
20-OH-LTB4, and LTB4) was observed at NAP/IL-8 concentrations >6 x 10-8
mol/liter. Half-maximal release occurred at 3.6 x 10 -a mol/liter. When 101 PMNL
were incubated with 10-6 mol/liter FMLP as control stimulus instead of NAP/IL-
8, in the presence of 8.2 x 10-6 mol/liter exogenous AA, 162 t 63 ng total pro-854
￿
INTERLEUKIN 8-INDUCED LEUKOTRIENE B4 PRODUCTION
J
Z
CL
O
y
c d
Y
3
N
-lo9 C NAP/ f L-8 [mol/l1
FIGURE 4 .
￿
Appearance ofÀA
metabolites in supernatant
fluids ofPMNL stimulated with
differentNAP/IL-8 concentra-
tions . 10' PMNL were in-
cubated in the presence of 8 x
10-6 mol/liter AA with dif-
ferent concentrations of NAP/
IL-8 for5min at 37°C . Super-
natants were analyzed by RP-
HPLC for AA metabolites .
Amounts of 20-COON-LTB4
(X), 20-OH-LTB4 (O), LTB4
(A), as well as the totalamount
of LTB4 produced (sum of 20-
COOH-LTB4, 20-OH-LTB4,
and LTB4)(0) were estimated
via determination of the peak
integral as described in Mate-
rials andMethods .When NAP/
IL-8 was used at concentrations
below 3 x 10-9 mol/liter LTB4
and 20-OH-LTB4 were esti-
matedvia the number ofhalf-
maximal effective doses to elicit
PMNL chemotaxis in putative
20-OH-LTB4- or LTB4-con-
taining fractions as described in
MaterialsandMethods. Results
of five experiments ± SD are
shown .
duced LTB4was detected (n = 11). NAP/IL-8-induced LTB4 production, therefore,
is in the same order as that found with FMLP as stimulus .
Time Course oftheAA Metabolite Profilefmm NAP/IL-8-stimulatedPMNL .
￿
5-Lipoxy-
genase activation in NAP/IL-8-stimulatedPMNL occurs very rapidly. Fig . 5 shows
that already 1 min after challenge with NAP/IL-8 one of the major arachidonate
metabolites is LTB4 . Also, both isomers, traps-LTB4 as well as epi-traps-LTB4, are
detectable, however, at low amounts . At that time nearly no 20-COOH-LTB4 is ob-
servable ; however, larger amounts of20-OH-LTB4 are present . LTB4 declines very
rapidly and is nearly absent after 40 min of incubation of the cells with NAP/IL-8 .
Maximal total LTB4 production (sum of 20-COOH-LTB4, 20-OH-LTB4, and
LTB4) occurred 40 min after stimulation with NAP/IL-8 . An additional finding is
the detectionof larger amounts of5-HETE only within 10 min after challenge, with
arapiddecline thereafter. Aftera40-min stimulation with NAP/IL-8, noUVabsorbing
peak at the position of 5-HETE is observable (Fig . 5) .
Availability of Exogenous AA for Leukotriene Production by NAP/IL-8-stimulated
PMNL . The detection of 5-lipoxygenase products in NAP/IL-8-stimulatedPMNL
is dependent upon the presence ofexogenousAA (Fig. 6) . When the total amount
of produced LTB4 is calculated by summing up the amounts of produced 20-
COOH-LTB4, 20-OH-LTB4, and LTB4 for determination of half-maximal totalZ
a
n
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N
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FIGURE 5.
￿
AppearanceofAA
metabolites in supernatants of
NAP/IL-8-stimulated PMNL
as a function of reaction time.
107 PMNL were incubated
with 6 x 10-s mol/liter NAP/
IL-8 in the presence of 8 x
10-6 mol/liter AA for various
time periods(0-40 min). Super-
natants were separated by RP-
HPLC and the amounts of
dilMTE derivatives (20-COOH-
LTB4 (o), 20-OH-LTB4 (A),
LTB4 (A), sum of trans-LTB4-
isomers (O), 5-HETE ("), and
the total amount of LTB4 pro-
duced (sum of 20-COOH-
LTB4, 20-OH-LTB4, and LTB4)
(X) wereestimated as described
in Materials and Methods.
Results ofa typical experiment
out of four experiments are
shown.
FIGURE 6.
￿
Production of AA
metabolitesby NAPAL-8-stim-
uiated PMNL as a function of
AA concentration. 107 PMNL
were preincubated with various
amounts of AA (3 x 10-7 to 8
10-6 mol/liter) followed by
ulatïon with 6 x 10-8 moll
liter NAPAL-8 for 5 min at
37°C. Supernatants were ana-
lyzed by RP-HPLC and the
amounts of 20-COOH-LTB4
(A), 20-OH-LTB4 (O), LTB4
(A), and the total produced
amounts of LTB4 (*) were es-
timated as described in Ma-
terials and Methods. Atconcen-
trations of AA below 8 x 10-7
mol/liter the amounts of LTB4
and 20-OH-LTB4 produced
were estimated via the number
of EDsp doses in the chemo-
taxis assay as described in Fig.
5 and Materials and Methods.
The mean of five experiments
t SD is shown.856
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LTB4 release, a concentration nearly 3 x 10-6 mol/literexogenous AA is necessary
(Fig. 6). When single metabolites were analyzed it appeared that with decreasing
amounts of exogenous AA the ratio of 20-COOH-LTB4/20-OH-LTB4/LTB4 in-
creases. Using exogenous AA at concentrations below 8 x 10' mol/liter UV
absorbing peaks at the positions ofleukotrienes and 5-HETE became so small that
UVdetection aloneis not sufficient for identificationofeicosanoids. Intheseexperi-
ments fractions corresponding to 20-OH-LTB4 as well as LTB4 were collected,
lyophilized, and analyzed for the number of ED5o doses by using the Boyden
chamber chemotaxis assay. In the system used, the ED5o for LTB4 and 20-OH-LTB4
corresponded to 1.3 x 10 -9 mol/liter and 9.5 x 10-9 mol/liter, respectively.
Significant amountsofPMNLchemotacticlipids elutingat theposition ofauthentic
20-OH-LTB4 and LTB4 were detected when cells were stimulated with NAP-IL-8
using AA concentrations higher than 3 x 10' mol/liter.
Further support was obtained by the use of 3H-labeled AA in these experiments.
Using a radioactivity detector after HPLC separation ofeicosanoids, radioactivity
peaks could be detected at the position of 20-COOH-LTB4, 20-OH-LTB4, LTB4,
and 5-HETE only when exogenous AA at concentrations higher than 2 x 10'
mol/liter (Fig. 3 C) was present. When 107 PMNL were stimulated with NAP/IL-8
in the presence of 2.5 pCi [3H]AA corresponding to 6.2 x 10-9 mol/liters AA, no
differences were observed in thebuffer control inthe radioactivityprofile afterHPLC
separation of incubation supernatants (Fig. 7, A and B). Similar results were ob-
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FIGURE 7. Stimulation of
PMNL with NAP/IL-8 in the
presence of [3H]AA. (A) 107
PMNL were incubatedwith 6
x 10-8 mol/liter NAP/IL-8 in
thepresence of2.5 uCi [3H]AA
(specific activity, 212Ci/mmol)
for 10 min at 37°C. Superna-
tants were separated by RP-
HPLC as described in Mate-
rials andMethodsandradioac-
tivity wasmonitoredby theuse
of on-line radiodetection with
continuous mixing with scintil-
latorfluid. Radioactivity eluting
from the column is shown as a
function of retention time.
Arrows indicate elutionposition
of authentic [3H]AA metabo-
lites ([3H]-20-COOH-LTB4
[3H]-LTB4 (III) ), , I[3H]-5 B--HETE
(IV)).(B)Showsthecontrolex-
periment, where instead of
NAP/IL-8 PBS was used. In
both cases a representative run
outofsixexperiments is shown.tained when PMNL pretreated with 5 hg/ml cytochalasin B were used (data not
shown). The majorpeaks seenintheradiochromatograms that represent only 0.1%
conversion of [3H]AA may be attributed to 12-HETE and 15-HETE, possibly in
part produced by some contaminating platelets or eosinophils, or may have been
nonenzymatically formed by autoxidation of[3H]AA during the incubation period.
Influence ofNAP/IL-8 Stimulation upon AA Release by PMNL.
￿
PMNL were incubated
with 5 uCi [3H]AA for an optimal time period of 1 h and (after washing) were then
stimulated for 5 min with 6 x 10-8 mol/liter NAP/IL-8 before HPLC separation
with on-line radioactivity monitoring. The results of such experiments, shown in
Fig. 8 A, indicate thatcompared with the control (Fig. 8 B), no significant amounts
of free [3H]AA or 5-lipoxygenase products were released after stimulation with
NAP/IL-8. Using the calcium ionophore A23187 as a control stimulus the typical
profile ofAA-metabolites including [3H]AA itself are observable (Fig. 8 C).
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FIGURE 8.
￿
InfluenceofNAP/
IL-8-activation upon releaseof
cellular [3H]AA and its metab-
olites in PMNL. 107 PMNL
were preincubated with 5pCi
Time [min]
￿
[3H]AA (specific activity, 212
Ci/mmol) for 1 hat 37°C. Cells
were washed and stimulated
thereafter either with 6 x 10-8
mol/liter NAP/IL-8, buffer, or
calcium ionophore A 23187 (8
x 10-6 mol/liter) in PBS con-
taining CaC12 andMgC12. Su-
pernatants were separated by
RP-HPLC and analyzed for
[3H]AA and its metabolites
with on-line radiodetection as
10
￿
0 30 t0
Time [min]
SCHRODER
￿
857
described in Materials and
Methods. (A)Experiment with
the use of NAPAL-8; (B) the
buffer control; and(G)showsas
a positive control the influence
ofCa-ionophore A23187 stim-
ulation upon releaseof cellular
[3H]AA and its metabolism.858 INTERLEUKIN 8-INDUCED LEUKOTRIENE B4 PRODUCTION
Discussion
Neutrophil chemotactic factors likeC5a, FMLP, orPAFhave been shown to acti-
vate the PMNL-AA-5-lipoxygenase (25-27, 33). Whereas the major product has
been identified as the 20-OH-metabolite ofLTB4, it has been possible with a short
incubation period to identify both LTB4 and 5-HETE as the main lipoxygenase
products (26). Our data demonstrate that NAP/IL-8, similar to other PMNL-
chemotactic factors, is also able to activate the PMNL-AA-5-lipoxygenase with the
formation of LTB4, 20-OH-LTB4, and 20-COOH-LTB4 as its main products at
NAP/IL-8 concentrations that elicit PMNL chemotaxis and the release ofprimary
granule constituents (13, 24). The ratio between these lipoxygenase products de-
pends upon the incubation time (Fig. 5) due to rapid w-oxidation ofinitially pro-
duced LTB4 by PMNL-LTB4 20-hydroxylase (34, 35). In addition to LTB4 and its
metabolites, both trans-isomers could be detected at low amounts. This supportsthe
suggestion that unstable LTA4 is formed by NAP/IL-8 activation of PMNL. The
latter isknownto hydrolyzenonenzymatically into biologicallyinactive trans-isomers
of LTB4 (36).
5-HETE, known as a productof5-lipoxygenase activation, is detectable in larger
amountsonlywithin 10 min ofincubation. I and others have obtained similarresults
using other more physiological stimuli for cellular activation, such as C5a, FMLP,
orPAF (25-27). The absence of 5-HETE aftera 20-min incubation might be the re-
sult ofincorporation into the cellular membrane (37) orformationofits S-lactone(38).
The total amounts ofLTB4 produced by NAP/IL-8 stimulation ofPMNL in the
presence of 8.2 x 10-6 mol/liter exogenous AA are lower than those seen with the
so far most powerful stimulus, calcium ionophore. In fact, NAP/IL-8 virtually does
not induce synthesis ofLTB4 in the absence ofor in the presence ofvery low con-
centrations (<10-' mol/liter) ofexogenous AA. Therefore, substrate availability ap-
pears to be a limiting factor for leukotriene production by NAP/IL-8 stimulation
ofPMNL. These results are in accordance with previous reports where only in the
presence ofexogenous AA could LTB4 be detected after stimulation with PMNL
chemotactic factors (25, 39, 40).
The amount of exogenously added AA required before LTB4 synthesis com-
menced has been found to be a point ofcontroversy. Apparently, excessive amounts
ofexogenous AA (30-250 1.M) are necessary in order to obtain significant produc-
tion of LTB4 or its metabolites following PMNL stimulation with chemotactic
factors (25, 26, 40). Moreover, it has been demonstrated that AA itself is able to
activate PMNL-5-LO athigh concentrations when given in ethanolic solution (41),
possibly due to membrane perturbation, increased trans-membrane penetration of
AA (42), or induction of additional cellular AA release by the vehicle (43).
In our studies we have avoided the use of ethanol. Also, instead of albumin as
a vehicle (25), which couldbind larger amountsofAA and therefore might decrease
the concentration of freely available substrate AA, we used sodium arachidonate.
In addition it was found that chemotactn-stimulated neutrophilspurified by theuse
of Ficoll or Percoll can produce substantially lower amounts of 5-LO metabolites
(unpublished results). Using a gelatin sedimentation techniquefor isolation ofcells,
PMNL ofnormal volunteers stimulated with 10-6 mol/liter FMLP in the presence
of 8.2 x 10-6 mol/liter AA produced 162 t 63 ng total LTB4 (sum of LTB4, 20-
OH-LTB4, and 20-COOH-LTB4) per 10' cells within 5 min of incubation . This isSCHRÜDER
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far above the amounts previously seen and may be attributedto the different stimu-
lation conditions used in our experiments.
Results obtained from experiments where PMNL were prelabeled with [3H]AA
indicate that NAP/IL-8 does not stimulate the release of membrane bound [3H]AA,
even at high concentrations of NAP/IL-8 (1.5 x 10-1 mol/liter). These findings are
somewhat different from those seen with the use ofFMLPas stimulus. Recent studies
with [3H]AA prelabeled PMNL have shown that 10-1 mol/liter FMLP is able to
release [3H]DiHETEs when cells were preincubated with cytochalasin B (33), which
is known to enhance the production of LTB4 up to fourfold, possibly by inhibiting
reacylation of AA into the cellular membrane (26).
We also have studied the effect of a cytochalasin B pretreatment of PMNL upon
the NAP-IL-8-induced release of leukotrienes and did not observe any significant
differences to experiments performed in the absence of cytochalasin B even when
NAP/IL-8 at 8 x 10"$ mol/liter was used (data not shown).
It appears that maximal LTB4 formation by PMNL in the absence of exogenously
added AA can only be achieved when the stimulus is a powerful activator of cellular
AA release and, in addition, an activator of the AA-5-lipoxygenase like the (non-
physiological) calcium ionophore A23187.
Recent observations indicate that several monokines including TNF enhance the
leukotriene generation in neutrophils stimulated with calcium ionophore A23187
(44, 45). More recent reports indicate that granulocyte/macrophage CSF (GM-CSF)
has a dramatic effect upon FMLP- or C5a-induced lipid metabolism stimulating
the release of substantial amounts of cellular arachidonic acid and LTB4 (41, 46).
It would be interesting to know whether also the NAP/IL-8-induced leukotriene
production in the absence ofexogenous addedAA is inducible by GM-CSF priming
of PMNL. This could be an explanation for a very recent finding indicating that
partially purified IL-1 preparations obtained from LPS-stimulated mononuclear cells,
which may contain both NAP/IL-8 and GM-CSF, stimulate LTB4 production in
the absence of exogenous AA in PMNL (47).
Furthermore, the suggestion that IL-1 itself is able to stimulate LTB4 production
and as stated recently (47), is not supported by our own findings: when superna-
tants of LPS-stimulated mononuclear cells were separated by preparative reversed-
phase HPLC no 5-lipoxygenase products were observed in supernatants of PMNL
stimulated with fractions containing IL-1 or with the use of human (h)rIL-lct in
the presence of exogenous AA. These findings were supported by recent investiga-
tions where neither hrIL-1cx or hrIL-lß were found to be able to activate PMNL
function (48, 49). It was concluded that there should exist a neutrophil-activating
factor (NAF) present in partially purified IL-1 preparations, which should be respon-
sible for leukotriene production and release of elastase in PMNL (49). The most
likely explanation would be that NAP/IL-8 is the cytokine responsible for the effect
seen in partially purified IL-1 preparations. NAP/IL-8 is known to elicit release of
PMNL primary granule constituents like ß-glucuronidase, myeloperoxidase, or
elastase in cytochalasin B-pretreated PMNL (13, 15, 24).
The observation that NAP/IL-8 is able to activate the neutrophil 5-lipoxygenase
might be of biological importance: in psoriasis, a noninfectious skin disease with
moderate to severe accumulation of neutrophils in the epidermis, LTB4-like mate-
rial has been found to be present in elevated amounts (50). In various investigations860
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we were able to show that themajorpart ofneutrophil chemotactic activity in aqueous
extracts of lesional psoriatic scales is due to a family of at least seven homologous
polypeptides called anionic neutrophil-activating peptide (ANAP) (51), wherebyone
of the main components, termed N2-ANAP, is by NH2-terminal sequencing, iden-
ticalwith NAPAL-8(52). Therefore, it is intriguing to speculate that NAP/IL-8 could
be a physiologically relevant activator of PMN-5-lipoxygenase when NAP/IL-8, to-
gether with exogenous AA, is present in large amounts in diseased tissue such as
in psoriatic lesions (52, 53).
In summary, we found that the novelhost cell-derived cytokine NAP/IL-8 is able
to activate the neutrophil 5-lipoxygenase, similarto otherclearly characterizedneu-
trophil chemotactic factors. A limiting step for induction of leukotriene synthesis
by NAP/IL-8 in PMNL appears to be the availability of exogenous AA. The lipid
mediators LTB4 and 20-OH-LTB4, which both are known to be potent neutrophil
chemotactic factors, appear to be of importance in amplifying inflammatory reac-
tions. The in vivo formation of these lipids is regulated by activators of the cellular
5-lipoxygenase and the availability of its substrate AA. Our results document apos-
sible central role of NAP/IL-8 as a proinflammatory mediator.
Summary
LPS and mitogen-stimulated mononuclearcells secrete a cytokine, which is able
to activate thePMNL-arachidonate-5-lipoxygenase. This cytokine has been proven
to be identical with the recently characterized novel neutrophil-activating peptide
NAP/IL-8. NAP/IL-8 is able to activate human PMNL for release of LTB4, W-oxi-
dized LTB4, and 5-HETE in the presence of exogenous AA. Half-maximal concen-
tration of NAP/IL-8 for release of LTB4 has been found to be near 4 x 10-$ mol/
liter. Time course studies revealed rapid activation ofPMNL, with maximal release
of LTB4 within the first 10 minwith a decline up to 40 min. High amounts of co-oxi-
dized LTB4 were detected up to that time. Significant amounts of AA-5-LO-pro-
ducts can be detected only when PMNL were stimulated with NAP/IL-8 in thepres-
ence of exogenous AA. The concentration of AA necessary for half-maximal LTB4
release has been found to be 3 x 10-6 mol/liter. In the presence of8 x 10-9 mol/liter
[3H]AA, NAP/IL-8 (10-9 to 10' mol/liter) did not induce the production of LTB4,
co-oxidized LTB4, or 5-HETE. In addition, PMNL prelabeled with [3H]AA did not
release either [3H]AA or 5-lipoxygenase metabolites when stimulated with NAP/
IL-8 (10-9 to 10-' mol/liter), indicating that NAP/IL-8 apparently does not activate
cellular phospholipases/diacylglycerol-lipases. Apart from FMLP, C5a, and PAF
NAP/IL-8 is the fourth clearlycharacterized neutrophil chemotaxin able to activate
the PMNL-5-lipoxygenase. The detection of large amounts of NAP/IL-8, arachi-
donic acid, as well as LTB4-like material, in lesional material of patients with psori-
asis points towards apossibly important role ofNAP/IL-8 in amplifying inflamma-
tory processes by induction of LTB4-production.
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